izpis_h1_title_alt

Proizvodnja terapevtskih monoklonskih protiteles v transgenih rastlinah
ID Svetina, Manca (Author), ID Luthar, Zlata (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (685,06 KB)
MD5: 43CD345F70F2440F568BDBE1F0496144

Abstract
Monoklonska protitelesa so največja skupina bioloških zdravil. Trenutno se uporabljajo pri zdravljenju rakavih obolenj, vnetnih in kardiovaskularnih boleznih, različnih okužbah, boleznih dihal, oftalmoloških boleznih ter pri transplantacijah organov. Za vsako zdravljenje so potrebni veliki odmerki dragih monoklonskih protiteles, ki jih trenutni proizvodni sistemi kmalu ne bodo več sposobni proizvesti. Večjo količino protiteles bi lahko pridobili z rastlinskimi proizvodnimi sistemi. Proizvodnja monoklonskih protiteles v rastlinah ima nekaj prednosti pred obstoječimi sistemi: je zelo prilagodljiva, hitra, poceni, globalno dostopna in ne predstavlja tveganja za okužbo z živalskimi patogeni. Za urejanje genoma in vključevanja novih lastnosti v rastline so na voljo obstoječe metode genskega inženiringa in nova učinkovita orodja, kot so: ZFNs, TALENs in CRISPR/Cas9. Izražanje monoklonskih protiteles v rastlinah dosežemo s stabilno transformacijo ali z začasno ekspresijo. Prva protitelesa so pridobili iz transgenih rastlin tobaka (Nicotiana tabacum L). Za uspešno prihodnjo uporabo so v transgenih rastlinah že proizvedli protitelesa, namenjena zdravljenju virusnih okužb (HIV, ebola, virus zahodnega Nila, junin virus, respiratorni sincicij virus in virus stekline), bakterijskih okužb (antraks, botulizem) in bolezni raka. Nekaj monoklonskih protiteles, sintetiziranih v transgenih rastlinah je že na različnih razvojnih stopnjah, vendar še nobeno ni v široki uporabi oziroma na farmacevtskem trgu.

Language:Slovenian
Keywords:genski inženiring, transgen, gensko spremenjene rastline, sinteza, terapevtiki, monoklonska protitelesa
Work type:Bachelor thesis/paper (mb11)
Typology:2.11 - Undergraduate Thesis
Organization:BF - Biotechnical Faculty
Year:2018
Publisher:[M. Svetina]
PID:20.500.12556/RUL-103066 This link opens in a new window
UDC:606:61:602.6:582:615.322(043.2)
COBISS.SI-ID:9036921 This link opens in a new window
Publication date in RUL:13.09.2018
Views:1126
Downloads:208
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Secondary language

Language:English
Title:Therapeutic monoclonal antibodies production in transgenic plants
Abstract:
Monoclonal antibodies are the largest class of biopharmaceuticals. They are currently utilized in therapies for cancer, inflammatory and cardiovascular diseases, various infections, respiratory diseases, ophthalmologic diseases and organ transplantations. For each treatment, we need large amounts of expensive monoclonal antibodies, which the current production systems soon won’t be able to produce. However, we could acquire a large number of antibodies with plant production systems. Production of monoclonal antibodies in plants has some advantages over the already existing systems: it is very adaptable, fast, cheap, globally accessible and does not pose a threat for an animal pathogen infection. For editing genome and integrating new properties into the plants the existing methods of genetic engineering and new efficient tools, like for example ZFNs, TALENs and CRISPR/Cas9 are available. We can achieve the expression of the monoclonal antibodies in plants with stable transformation or with transient (temporary) expression. The first plant antibodies were obtained from transgenic tobacco plants (Nicotiana tabacum L). For a successful usage of the transgenic plants in the future, the monoclonal antibodies for treating viral infections (human immunodeficiency virus, Ebola virus, West Nile virus, Junin virus, respiratory syncytial virus and rabies), bacterial infections (anthrax, botulism) and cancerous diseases were produced inside them. Some of the monoclonal antibodies synthesized in the transgenic plants are already at variable development stages, but none of them are in wide-range use or on the pharmaceutical market.

Keywords:genetic engineering, transgen, genetically modified plants, synthesis, therapeutics, monoclonal antibodies

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back